FDA mulls behind-the-counter drug category

Share this article:

The FDA said it may create a new “behind-the-counter” (BTC) category of drugs made available at drugstores to patients without a prescription, but only after consultation with a pharmacist.

The agency will hold a public meeting to hear feedback about on the BTC concept on Nov. 14. The purpose of the meeting is to solicit information and views on specific issues associated with BTC availability.
There are currently only a few drugs available BTC in the US – one is Barr's Plan B birth control drug.

However, countries such as Australia, Canada and New Zealand use the BTC system more widely.

According to the FDA, the criteria generally used BTC status in other countries include suitability for self-diagnosis and a low potential for serious side effects and overdose.

“Because pharmacists have the training and knowledge to provide certain interventions, they may be able to ensure that patients meet the conditions for use and educate patients on appropriate use of the drug product,” the FDA said in a Federal Register notice.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.